Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer
An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 m...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2022-01, Vol.160, p.227-234 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 234 |
|---|---|
| container_issue | |
| container_start_page | 227 |
| container_title | European journal of cancer (1990) |
| container_volume | 160 |
| creator | Mizugaki, Hidenori Oizumi, Satoshi Fujita, Yuka Harada, Toshiyuki Nakahara, Yoshiro Takashina, Taichi Ko, Ryo Watanabe, Kageaki Hotta, Takamasa Minemura, Hiroyuki Saeki, Sho Asahina, Hajime Nakamura, Keiichi Nakamura, Hiromi Hosoda, Fumie Yagishita, Shigehiro Hamada, Akinobu |
| description | An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters.
The primary end-point was the objective response rate (ORR), and the planned number of registered cases was 35, with a threshold ORR of 50%, an expected ORR of 75%, α of 0.05, and β of 0.1. Secondary end-points were progression-free survival (PFS), overall survival (OS), the incidence rate of adverse events (AEs), QOL survey (FACT-L), and trough plasma concentration of afatinib at steady state (Css) and at the occurrence of clinically significant AEs.
The median age of the patients was 79 years. The ORR was 80.0% and the disease control rate was 91.4%. The median PFS and OS were 15.6 and 29.5 months, respectively. Four patients discontinued because of AEs. Treatment-related death was not observed. No significant change in QOL was observed at baseline and after 4, 8, and 12 weeks. Css was comparable with those in previous reports and was significantly higher in patients with grade 3 AEs. Direct correlations between afatinib treatment and PGx profiles were not observed.
An afatinib starting dose of 30 mg/day could be an effective and safe treatment option for elderly patients.
•Objective response rate was 80.0% and disease control rate was 91.4%.•Progression-free and overall survival were 15.6 and 29.5 months, respectively.•Plasma level of 30 mg afatinib was comparable with that of LUX-LUNG studies.•Plasma afatinib level in patients with grade 3 adverse events was relatively high.•Afatinib starting dose of 30 mg/day may be effective for elderly patients. |
| doi_str_mv | 10.1016/j.ejca.2021.10.024 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2625331354</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804921011825</els_id><sourcerecordid>2625331354</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-eea030128ba3c3d70d0b7cbf6853ab4ea7f01807a8601a6c18fa70bd9d481adb3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EotvCC3BAljhnGcf540hcUNWWSpVACM6WY09ah8QOttNqb7xDLzwfT4KXXThymZF-880nzXyEvGKwZcCat-MWR622JZQsgy2U1ROyYaLtChB1-ZRsoKu7QkDVnZDTGEcAaEUFz8kJr0RTguAb8vPTnQqz0v6bdZispsoZuhzZLTo__2Fq2kUbqR_o5B8K4yNSNahkne1pCqjSjC5R6yhOBsO0o0seZhTpg0139OLq8jOd15Shd8Xio032Hqnz7tePxziraaIac5lWd0u1chrDC_JsUFPEl8d-Rr5eXnw5_1DcfLy6Pn9_U-iy61KBqIADK0WvuOamBQN9q_uhETVXfYWqHYAJaJVogKlGMzGoFnrTmUowZXp-Rt4cfJfgv68Ykxz9GvLBUZZNWXPOeF1lVXlQ6eBjDDjIJdhZhZ1kIPdhyFHuw5D7MPYsh5GXXh-t135G82_l7_ez4N1BgPnAe4tBRp2_ptHYgDpJ4-3__H8DYb-fiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2625331354</pqid></control><display><type>article</type><title>Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Mizugaki, Hidenori ; Oizumi, Satoshi ; Fujita, Yuka ; Harada, Toshiyuki ; Nakahara, Yoshiro ; Takashina, Taichi ; Ko, Ryo ; Watanabe, Kageaki ; Hotta, Takamasa ; Minemura, Hiroyuki ; Saeki, Sho ; Asahina, Hajime ; Nakamura, Keiichi ; Nakamura, Hiromi ; Hosoda, Fumie ; Yagishita, Shigehiro ; Hamada, Akinobu</creator><creatorcontrib>Mizugaki, Hidenori ; Oizumi, Satoshi ; Fujita, Yuka ; Harada, Toshiyuki ; Nakahara, Yoshiro ; Takashina, Taichi ; Ko, Ryo ; Watanabe, Kageaki ; Hotta, Takamasa ; Minemura, Hiroyuki ; Saeki, Sho ; Asahina, Hajime ; Nakamura, Keiichi ; Nakamura, Hiromi ; Hosoda, Fumie ; Yagishita, Shigehiro ; Hamada, Akinobu</creatorcontrib><description>An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters.
The primary end-point was the objective response rate (ORR), and the planned number of registered cases was 35, with a threshold ORR of 50%, an expected ORR of 75%, α of 0.05, and β of 0.1. Secondary end-points were progression-free survival (PFS), overall survival (OS), the incidence rate of adverse events (AEs), QOL survey (FACT-L), and trough plasma concentration of afatinib at steady state (Css) and at the occurrence of clinically significant AEs.
The median age of the patients was 79 years. The ORR was 80.0% and the disease control rate was 91.4%. The median PFS and OS were 15.6 and 29.5 months, respectively. Four patients discontinued because of AEs. Treatment-related death was not observed. No significant change in QOL was observed at baseline and after 4, 8, and 12 weeks. Css was comparable with those in previous reports and was significantly higher in patients with grade 3 AEs. Direct correlations between afatinib treatment and PGx profiles were not observed.
An afatinib starting dose of 30 mg/day could be an effective and safe treatment option for elderly patients.
•Objective response rate was 80.0% and disease control rate was 91.4%.•Progression-free and overall survival were 15.6 and 29.5 months, respectively.•Plasma level of 30 mg afatinib was comparable with that of LUX-LUNG studies.•Plasma afatinib level in patients with grade 3 adverse events was relatively high.•Afatinib starting dose of 30 mg/day may be effective for elderly patients.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2021.10.024</identifier><identifier>PMID: 34862083</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Afatinib - pharmacokinetics ; Afatinib - pharmacology ; Afatinib - therapeutic use ; Aged ; Aging ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Disease control ; EGFR mutation ; Elderly patients ; Epidermal growth factor receptors ; Female ; Geriatrics ; Humans ; Low-dose afatinib ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Mutation ; Non-small cell lung carcinoma ; Older people ; Patients ; Pharmacogenomics ; Pharmacokinetics ; Pharmacology ; Population studies ; Progression-Free Survival ; Protein Kinase Inhibitors - pharmacokinetics ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Quality assessment ; Small cell lung carcinoma ; Survival</subject><ispartof>European journal of cancer (1990), 2022-01, Vol.160, p.227-234</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jan 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-eea030128ba3c3d70d0b7cbf6853ab4ea7f01807a8601a6c18fa70bd9d481adb3</citedby><cites>FETCH-LOGICAL-c299t-eea030128ba3c3d70d0b7cbf6853ab4ea7f01807a8601a6c18fa70bd9d481adb3</cites><orcidid>0000-0002-7126-3153 ; 0000-0002-8420-5606 ; 0000-0001-8710-1960</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2021.10.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34862083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mizugaki, Hidenori</creatorcontrib><creatorcontrib>Oizumi, Satoshi</creatorcontrib><creatorcontrib>Fujita, Yuka</creatorcontrib><creatorcontrib>Harada, Toshiyuki</creatorcontrib><creatorcontrib>Nakahara, Yoshiro</creatorcontrib><creatorcontrib>Takashina, Taichi</creatorcontrib><creatorcontrib>Ko, Ryo</creatorcontrib><creatorcontrib>Watanabe, Kageaki</creatorcontrib><creatorcontrib>Hotta, Takamasa</creatorcontrib><creatorcontrib>Minemura, Hiroyuki</creatorcontrib><creatorcontrib>Saeki, Sho</creatorcontrib><creatorcontrib>Asahina, Hajime</creatorcontrib><creatorcontrib>Nakamura, Keiichi</creatorcontrib><creatorcontrib>Nakamura, Hiromi</creatorcontrib><creatorcontrib>Hosoda, Fumie</creatorcontrib><creatorcontrib>Yagishita, Shigehiro</creatorcontrib><creatorcontrib>Hamada, Akinobu</creatorcontrib><title>Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters.
The primary end-point was the objective response rate (ORR), and the planned number of registered cases was 35, with a threshold ORR of 50%, an expected ORR of 75%, α of 0.05, and β of 0.1. Secondary end-points were progression-free survival (PFS), overall survival (OS), the incidence rate of adverse events (AEs), QOL survey (FACT-L), and trough plasma concentration of afatinib at steady state (Css) and at the occurrence of clinically significant AEs.
The median age of the patients was 79 years. The ORR was 80.0% and the disease control rate was 91.4%. The median PFS and OS were 15.6 and 29.5 months, respectively. Four patients discontinued because of AEs. Treatment-related death was not observed. No significant change in QOL was observed at baseline and after 4, 8, and 12 weeks. Css was comparable with those in previous reports and was significantly higher in patients with grade 3 AEs. Direct correlations between afatinib treatment and PGx profiles were not observed.
An afatinib starting dose of 30 mg/day could be an effective and safe treatment option for elderly patients.
•Objective response rate was 80.0% and disease control rate was 91.4%.•Progression-free and overall survival were 15.6 and 29.5 months, respectively.•Plasma level of 30 mg afatinib was comparable with that of LUX-LUNG studies.•Plasma afatinib level in patients with grade 3 adverse events was relatively high.•Afatinib starting dose of 30 mg/day may be effective for elderly patients.</description><subject>Afatinib - pharmacokinetics</subject><subject>Afatinib - pharmacology</subject><subject>Afatinib - therapeutic use</subject><subject>Aged</subject><subject>Aging</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Disease control</subject><subject>EGFR mutation</subject><subject>Elderly patients</subject><subject>Epidermal growth factor receptors</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Low-dose afatinib</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Older people</subject><subject>Patients</subject><subject>Pharmacogenomics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Population studies</subject><subject>Progression-Free Survival</subject><subject>Protein Kinase Inhibitors - pharmacokinetics</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quality assessment</subject><subject>Small cell lung carcinoma</subject><subject>Survival</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EotvCC3BAljhnGcf540hcUNWWSpVACM6WY09ah8QOttNqb7xDLzwfT4KXXThymZF-880nzXyEvGKwZcCat-MWR622JZQsgy2U1ROyYaLtChB1-ZRsoKu7QkDVnZDTGEcAaEUFz8kJr0RTguAb8vPTnQqz0v6bdZispsoZuhzZLTo__2Fq2kUbqR_o5B8K4yNSNahkne1pCqjSjC5R6yhOBsO0o0seZhTpg0139OLq8jOd15Shd8Xio032Hqnz7tePxziraaIac5lWd0u1chrDC_JsUFPEl8d-Rr5eXnw5_1DcfLy6Pn9_U-iy61KBqIADK0WvuOamBQN9q_uhETVXfYWqHYAJaJVogKlGMzGoFnrTmUowZXp-Rt4cfJfgv68Ykxz9GvLBUZZNWXPOeF1lVXlQ6eBjDDjIJdhZhZ1kIPdhyFHuw5D7MPYsh5GXXh-t135G82_l7_ez4N1BgPnAe4tBRp2_ptHYgDpJ4-3__H8DYb-fiA</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Mizugaki, Hidenori</creator><creator>Oizumi, Satoshi</creator><creator>Fujita, Yuka</creator><creator>Harada, Toshiyuki</creator><creator>Nakahara, Yoshiro</creator><creator>Takashina, Taichi</creator><creator>Ko, Ryo</creator><creator>Watanabe, Kageaki</creator><creator>Hotta, Takamasa</creator><creator>Minemura, Hiroyuki</creator><creator>Saeki, Sho</creator><creator>Asahina, Hajime</creator><creator>Nakamura, Keiichi</creator><creator>Nakamura, Hiromi</creator><creator>Hosoda, Fumie</creator><creator>Yagishita, Shigehiro</creator><creator>Hamada, Akinobu</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><orcidid>https://orcid.org/0000-0002-7126-3153</orcidid><orcidid>https://orcid.org/0000-0002-8420-5606</orcidid><orcidid>https://orcid.org/0000-0001-8710-1960</orcidid></search><sort><creationdate>202201</creationdate><title>Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer</title><author>Mizugaki, Hidenori ; Oizumi, Satoshi ; Fujita, Yuka ; Harada, Toshiyuki ; Nakahara, Yoshiro ; Takashina, Taichi ; Ko, Ryo ; Watanabe, Kageaki ; Hotta, Takamasa ; Minemura, Hiroyuki ; Saeki, Sho ; Asahina, Hajime ; Nakamura, Keiichi ; Nakamura, Hiromi ; Hosoda, Fumie ; Yagishita, Shigehiro ; Hamada, Akinobu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-eea030128ba3c3d70d0b7cbf6853ab4ea7f01807a8601a6c18fa70bd9d481adb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Afatinib - pharmacokinetics</topic><topic>Afatinib - pharmacology</topic><topic>Afatinib - therapeutic use</topic><topic>Aged</topic><topic>Aging</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Disease control</topic><topic>EGFR mutation</topic><topic>Elderly patients</topic><topic>Epidermal growth factor receptors</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Low-dose afatinib</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Older people</topic><topic>Patients</topic><topic>Pharmacogenomics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Population studies</topic><topic>Progression-Free Survival</topic><topic>Protein Kinase Inhibitors - pharmacokinetics</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quality assessment</topic><topic>Small cell lung carcinoma</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mizugaki, Hidenori</creatorcontrib><creatorcontrib>Oizumi, Satoshi</creatorcontrib><creatorcontrib>Fujita, Yuka</creatorcontrib><creatorcontrib>Harada, Toshiyuki</creatorcontrib><creatorcontrib>Nakahara, Yoshiro</creatorcontrib><creatorcontrib>Takashina, Taichi</creatorcontrib><creatorcontrib>Ko, Ryo</creatorcontrib><creatorcontrib>Watanabe, Kageaki</creatorcontrib><creatorcontrib>Hotta, Takamasa</creatorcontrib><creatorcontrib>Minemura, Hiroyuki</creatorcontrib><creatorcontrib>Saeki, Sho</creatorcontrib><creatorcontrib>Asahina, Hajime</creatorcontrib><creatorcontrib>Nakamura, Keiichi</creatorcontrib><creatorcontrib>Nakamura, Hiromi</creatorcontrib><creatorcontrib>Hosoda, Fumie</creatorcontrib><creatorcontrib>Yagishita, Shigehiro</creatorcontrib><creatorcontrib>Hamada, Akinobu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mizugaki, Hidenori</au><au>Oizumi, Satoshi</au><au>Fujita, Yuka</au><au>Harada, Toshiyuki</au><au>Nakahara, Yoshiro</au><au>Takashina, Taichi</au><au>Ko, Ryo</au><au>Watanabe, Kageaki</au><au>Hotta, Takamasa</au><au>Minemura, Hiroyuki</au><au>Saeki, Sho</au><au>Asahina, Hajime</au><au>Nakamura, Keiichi</au><au>Nakamura, Hiromi</au><au>Hosoda, Fumie</au><au>Yagishita, Shigehiro</au><au>Hamada, Akinobu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2022-01</date><risdate>2022</risdate><volume>160</volume><spage>227</spage><epage>234</epage><pages>227-234</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-arm, and open-label phase II trial for low-dose afatinib (30 mg/day) use in elderly patients with NSCLC with EGFR mutation to assess quality-of-life (QOL) and pharmacokinetic (PK)/pharmacogenomic (PGx) parameters.
The primary end-point was the objective response rate (ORR), and the planned number of registered cases was 35, with a threshold ORR of 50%, an expected ORR of 75%, α of 0.05, and β of 0.1. Secondary end-points were progression-free survival (PFS), overall survival (OS), the incidence rate of adverse events (AEs), QOL survey (FACT-L), and trough plasma concentration of afatinib at steady state (Css) and at the occurrence of clinically significant AEs.
The median age of the patients was 79 years. The ORR was 80.0% and the disease control rate was 91.4%. The median PFS and OS were 15.6 and 29.5 months, respectively. Four patients discontinued because of AEs. Treatment-related death was not observed. No significant change in QOL was observed at baseline and after 4, 8, and 12 weeks. Css was comparable with those in previous reports and was significantly higher in patients with grade 3 AEs. Direct correlations between afatinib treatment and PGx profiles were not observed.
An afatinib starting dose of 30 mg/day could be an effective and safe treatment option for elderly patients.
•Objective response rate was 80.0% and disease control rate was 91.4%.•Progression-free and overall survival were 15.6 and 29.5 months, respectively.•Plasma level of 30 mg afatinib was comparable with that of LUX-LUNG studies.•Plasma afatinib level in patients with grade 3 adverse events was relatively high.•Afatinib starting dose of 30 mg/day may be effective for elderly patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34862083</pmid><doi>10.1016/j.ejca.2021.10.024</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7126-3153</orcidid><orcidid>https://orcid.org/0000-0002-8420-5606</orcidid><orcidid>https://orcid.org/0000-0001-8710-1960</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2022-01, Vol.160, p.227-234 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_journals_2625331354 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Afatinib - pharmacokinetics Afatinib - pharmacology Afatinib - therapeutic use Aged Aging Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Disease control EGFR mutation Elderly patients Epidermal growth factor receptors Female Geriatrics Humans Low-dose afatinib Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Mutation Non-small cell lung carcinoma Older people Patients Pharmacogenomics Pharmacokinetics Pharmacology Population studies Progression-Free Survival Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Quality assessment Small cell lung carcinoma Survival |
| title | Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non–small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A46%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20and%20pharmacogenomic%20analysis%20of%20low-dose%20afatinib%20treatment%20in%20elderly%20patients%20with%20EGFR%20mutation-positive%20non%E2%80%93small%20cell%20lung%20cancer&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Mizugaki,%20Hidenori&rft.date=2022-01&rft.volume=160&rft.spage=227&rft.epage=234&rft.pages=227-234&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2021.10.024&rft_dat=%3Cproquest_cross%3E2625331354%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2625331354&rft_id=info:pmid/34862083&rft_els_id=S0959804921011825&rfr_iscdi=true |